内皮素受体拮抗剂与SGLT2抑制剂单用及联用治疗IgA肾病的随机交叉试验
结果显示两药降低蛋白尿的作用无相关性;联用降低24小时UPCR 44%,与安立生坦单用相似但优于恒格列净单用,且液体潴留少于安立生坦单用。
要点
- 内皮素受体拮抗剂与SGLT2抑制剂降蛋白尿效应无相关性
- 两药联用降蛋白尿优于SGLT2抑制剂单用,与内皮素受体拮抗剂单用相似
- 联用液体潴留和体重增加明显少于内皮素受体拮抗剂单用
核心结论
- 内皮素受体拮抗剂联合SGLT2抑制剂较SGLT2抑制剂单用进一步降低蛋白尿,且液体潴留少于内皮素受体拮抗剂单用。
研究设计与样本
- 受试者随机顺序接受安立生坦5 mg/d、恒格列净10 mg/d及两药联用,各治疗4周后洗脱4周。
主要发现
- 单药与联用降低24小时UPCR无相关性(安立生坦r=0.13,P=0.97;恒格列净r=0.04,P=1.00)。
- 联用组24小时UPCR平均降低44%(95%CI -52至-34),与安立生坦单用(-48%,95%CI -56至-39)相似,优于恒格列净单用(-21%,95%CI -33至-6)。
- 联用组eGFR平均较基线下降4.7 ml/min per 1.73 m²(95%CI -6.9至-2.6),大于安立生坦单用(-0.5 ml/min per 1.73 m²,95%CI -2.8至1.9),与恒格列净单用(-3.5 ml/min per 1.73 m²,95%CI -5.8至-1.2)相当。
- 联用组液体潴留(体重变化)少于安立生坦单用。
临床怎么用
- 对最大耐受RAS阻断后仍有蛋白尿的IgA肾病患者,可考虑内皮素受体拮抗剂联合SGLT2抑制剂以进一步降蛋白尿并减少液体潴留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Proteinuria responses to endothelin receptor antagonists and sodium-glucose cotransporter 2 inhibitors were not correlated. Ambrisentan-henagliflozin combination therapy reduced proteinuria similarly to ambrisentan monotherapy but exceeded henagliflozin alone. Combination therapy resulted in markedly less fluid retention and weight gain compared with endothelin receptor antagonist monotherapy. BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and endothelin receptor antagonists (ERAs) can reduce proteinuria and may slow kidney progression in IgA nephropathy. Their potential synergistic efficacy and safety are unclear. METHODS: This open-label randomized crossover trial enrolled adults with IgA nephropathy, eGFR >30 ml/min per 1.73 m 2 , and 24-hour urine protein-creatinine ratio (UPCR) ≥0.44 g/g or 24-hour urine protein ≥0.5 g, despite maximal renin-angiotensin system blockade. Treatments were given in random order (ambrisentan 5 mg/d, henagliflozin 10 mg/d, and combination), each for 4 weeks followed by a 4-week washout. Primary end point was correlation between treatments in 24-hour UPCR changes. Secondary end points included eGFR change. Safety end points included fluid retention (body weight change). RESULTS: Sixty-five patients were enrolled, with a mean baseline eGFR of 69 ml/min per 1.73 m 2 (SD=23) and a median 24-hour UPCR of 0.8 g/g (0.6-1.3). No correlation was found in 24-hour UPCR reduction between single-agent therapy and combination therapy (ambrisentan, r =0.13, P = 0.97; henagliflozin, r =0.04, P = 1.00). After treatment, the mean reduction in 24-hour UPCR was -44% with combination therapy (95% confidence interval [CI], -52 to -34), which was similar to ambrisentan alone (-48%; 95% CI, -56 to -39) but significantly superior to henagliflozin alone (-21%; 95% CI, -33 to -6). The mean reduction in eGFR from baseline was -4.7 ml/min per 1.73 m 2 (95% CI, -6.9 to -2.6) with combination therapy, which was significantly greater than with ambrisentan (-0.5 ml/min per 1.73 m 2 ; 95% CI, -2.8 to 1.9) but comparable with henagliflozin (-3.5 ml/min per 1.73 m 2 ; 95% CI, -5.8 to -1.2). Less fluid retention occurred with combination treatment versus ambrisentan alone. CONCLUSIONS: Combining an ERA with an SGLT2 inhibitor further reduced proteinuria versus SGLT2 inhibitor alone, with less fluid retention than ERA alone. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Chinese Clinical Trial Registry (ChiCTR2400080435).
引用
- Chen Q, Chen P, Liu L, et al. Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial. J Am Soc Nephrol. 2026. PMID: 41949916. doi:10.1681/ASN.0000001097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。